Certara

Company profile

About Certara

Certara is a global leader in drug development solutions, serving the pharmaceutical, biotechnology, and contract research organization (CRO) sectors. With over 1,550 employees across more than 30 countries—28% holding PhDs—Certara integrates science, technology, and regulatory expertise to transform drug development from molecule to market. The company's comprehensive portfolio spans software platforms and professional services that address every phase of drug development, from discovery through market access and commercialization. Certara's software solutions include Phoenix for PK/PD analysis, Simcyp for physiologically-based pharmacokinetic (PBPK) modeling, Pinnacle 21 for data standardization and validation, GlobalSubmit for eCTD submissions, BaseCase for market access value stories, and Certara.AI—an AI platform designed specifically for life sciences. The company's CoAuthor platform leverages generative AI for regulatory writing, while D360 provides scientific informatics for molecular analysis. On the services side, Certara offers modeling and simulation, biometrics and data science, drug development support, regulatory strategy, and real-world evidence and market access consulting. The company specializes in Model-Informed Drug Development (MIDD), using predictive biosimulation to reduce development risk and accelerate decision-making. Certara maintains Centers of Excellence addressing complex therapeutic challenges in oncology, pediatrics, rare diseases, and other specialized areas. The company's mission is to transform drug development for good, helping clients optimize trial design, achieve regulatory milestones, demonstrate value to payers, and ultimately bring safer, more effective therapies to patients worldwide.

Company description · Certara official website